Fig 1.
Perceived COVID-19-Related Risk Scale score for Psoriasis.
Perceived COVID-19-Related Risk Scale score for Psoriasis stratified by demographic and psoriasis disease characteristics. PASI, Psoriasis Area and Severity Index, PsA, psoriatic arthritis, PsO, cutaneous psoriasis. Bars for each estimate indicate the standard error of the mean. #Friends or a family member with or without quarantine experience. *P < 0.05; ** P < 0.01, ***P < 0.001. Comparisons between groups were performed using the Mann–Whitney U test except for the subgroups that were stratified by PASI and treatment modalities, assessed using the Kruskal–Wallis test.
Table 1.
Participant demographic and disease characteristics.
Fig 2.
Psychological impact of the COVID-19 pandemic.
Comparison of scores from the IES-R and a scale measuring DAISS between psoriasis patients who were stratified by psoriasis severity and comorbidity. PASI, Psoriasis Area, and Severity Index. *P < 0.05; ** P < 0.01, ***P < 0.001. Comparisons between groups stratified by PASI and comorbidity were performed using the Kruskal–Wallis test and the Mann–Whitney U test, respectively.
Fig 3.
Healthcare-seeking behavior changes.
Changes in healthcare-seeking behaviors in psoriasis patients during the COVID-19 pandemic among psoriasis patients stratified by perceived COVID-19-related risk (average PCRSP score, aPCRSP), duration of psoriasis, and friends or a family member with and without quarantine experience. * Quarantine_Y, Friends or a family member with quarantine experience, Quarantine_N, Friends or a family member without quarantine experience.
Table 2.
Results of multiple linear regression on factors associated with PCRSP, DAISS, and IES-R.